Back to SVNT Stock Lookup

SVNT Related Analyst Ratings

May 17, 2013 06:47 AM William Blair Downgrades Savient Pharmaceuticals (SVNT) to Market Perform

Apr 20, 2012 10:05 AM Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect

Mar 26, 2012 09:05 AM Canaccord Genuity Starts Savient Pharmaceuticals (SVNT) at Hold

Mar 1, 2012 08:26 AM William Blair Starts Savient Pharmaceuticals (SVNT) at Outperform

Feb 2, 2012 01:46 PM Jefferies Maintains an 'Underperform' on Savient Pharmaceuticals (SVNT); CEO Resigns After Short Tenure

Feb 1, 2012 10:15 AM Cowen Downgrades Savient Pharmaceuticals (SVNT) to Neutral

Nov 10, 2011 08:11 AM JMP Securities Downgrades Savient Pharmaceuticals (SVNT) to Market Underperform

Jul 14, 2011 08:07 AM Leerink Swann Upgrades Savient Pharmaceuticals (SVNT) to Market Perform; Estimates Have Come Down, But May Be Met

Jun 22, 2011 07:59 AM Citadel Securities Maintains a 'Neutral' on Savient Pharmaceuticals (SVNT); Ilaris FDA Panel Rejection Removes Potential Krystexxa Adoption Overhang

May 20, 2011 07:19 AM Citadel Securities Downgrades Savient Pharmaceuticals (SVNT) to Neutral; Krystexxa Ramp On Hold

May 9, 2011 08:31 AM Lazard Capital Downgrades Savient Pharmaceuticals (SVNT) to Hold

May 6, 2011 09:21 AM JPMorgan Downgrades Savient Pharmaceuticals (SVNT) to Neutral

May 5, 2011 01:45 PM Savient (SVNT) Shares Sink Midday as Leerink Cuts to Underperform

Apr 11, 2011 02:49 PM Wedbush Assumes Coverage on Savient Pharma (SVNT) at Outperform, $15 Target

Apr 6, 2011 05:52 PM Citadel Securities Starts Savient Pharmaceuticals (SVNT) at Add, Sees Much Potential For an Upside

Apr 6, 2011 05:15 PM Mizuho Starts Biotech Stocks: (AMGN) (BIIB) (CELG) (ONXX) (RDEA) at Buy, (SVNT) at Neutral

Dec 29, 2010 09:42 AM Soleil Securities Calls Savient Pharmaceuticals (SVNT) CEO Search An Important Step in the Right Direction

Dec 29, 2010 09:34 AM Wedbush Said Savient Pharmaceuticals' (SVNT) CEO Search Could Suggest Near-Term Sale Is Off the Table

Dec 1, 2010 09:25 AM Global Hunter Securities Reiterates a 'Buy' on Savient Pharmaceuticals (SVNT); Stock Significantly Undervalued

Dec 1, 2010 07:49 AM JMP Securities Upgrades Savient Pharmaceuticals (SVNT) to Market Outperform

Nov 8, 2010 08:54 AM Soleil Securities Upgrades Savient Pharmaceuticals (SVNT) to Buy; Lowering Krystexxa Estimates, but SVNT is Oversold

Oct 28, 2010 08:39 AM Cowen & Co Upgrades Savient Pharmaceuticals (SVNT) to Outperform

Oct 27, 2010 08:22 AM JMP Securities Downgrades Savient Pharmaceuticals (SVNT) to Market Perform

Oct 26, 2010 03:52 PM Global Hunter Securities Cuts Price Target on Savient Pharmaceuticals (SVNT) to $15, But Maintains 'Buy'

Oct 5, 2010 08:40 AM Savient Pharma (SVNT) Cut to Neutral at Cowen

Sep 30, 2010 07:44 AM Soleil Downgrades Savient Pharma (SVNT) to Hold; Sees Limited Upside Despite Possible M&A Activity

Sep 21, 2010 07:20 AM Leerink Swann Downgrades Savient Pharmaceuticals (SVNT) to Market Perform; M&A, Launch and Competitive Uncertainty

Sep 16, 2010 08:32 AM Global Hunter Securities Reiterates a 'Buy' on Savient Pharmaceuticals (SVNT); Acquisition Talks Continue; No Salesforce Identified Yet

Sep 16, 2010 08:10 AM Oppenheimer Downgrades Savient Pharmaceuticals (SVNT) to Perform

Sep 15, 2010 02:40 PM Savient (SVNT): FDA Approval "Check", M&A Next

Sep 15, 2010 02:38 PM Leerink Swann Raises Target on Savient (SVNT) to $22; Highlights Takeover Potential Following Krystexxa Approval

Sep 15, 2010 01:47 PM Wedbush Maintains an 'Outperform' on Savient Pharmaceuticals (SVNT); Raising PT on Potential Takeout in the Near Term

Aug 5, 2010 08:38 AM BofA/Merrill Lynch Upgrades Savient Pharmaceuticals (SVNT) to 'Neutral'

Jul 12, 2010 12:14 PM Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)

Jul 9, 2010 02:47 PM Wedbush Assumes Savient (SVNT), Starts Ardea (RDEA) at Outperform

Jun 29, 2010 03:45 PM Global Hunter Securities Suggest Investors Acquire a Basket of Biotech Stocks

Jun 29, 2010 08:09 AM Global Hunter Securities Initiates Coverage on Several Biotech Stocks; Sees Glass "Half Full"

Mar 25, 2010 09:54 AM BofA/Merrill Lynch Initiates Coverage on Several Biotechnology and Drugs Stocks; Upgrades ALXN

Jan 28, 2010 07:32 AM Soleil Securities Initiates Coverage on Savient Pharmaceuticals (SVNT) with a Buy

Dec 4, 2009 07:30 AM JPMorgan Starts Savient (SVNT) at Overweight

Oct 9, 2009 08:22 AM Oppenheimer Upgrades Savient Pharmaceuticals (SVNT) to Outperform

Aug 4, 2009 07:33 AM Jefferies & Co Downgrades Savient Pharmaceuticals (SVNT) to Underperform

Aug 3, 2009 03:07 PM Savient Pharma (SVNT) Lower On FDA Refusal of Gout Treatment, But Analysts Still Positive

Jul 31, 2009 09:12 AM Wedbush Morgan Comments On Savient (SVNT) Ahead of FDA PDUFA Date

Jun 17, 2009 02:04 PM JMP Starts Savient (SVNT) at Market Outperform

Jun 17, 2009 08:34 AM Oppenheimer & Cowen Upgrades Savient Pharmaceuticals (SVNT) on FDA Panel News

Jun 15, 2009 01:09 PM Wall Street Access Upgrades Savient Pharmaceuticals (SVNT) to Buy

Dec 19, 2008 10:53 AM Roth Capital Starts Savient Pharma (SVNT) at Buy

Nov 25, 2008 01:20 PM Oppenheimer Downgrades Savient Pharma (SVNT) to Underperform

Oct 27, 2008 09:25 AM Cowen & Co Downgrades Savient Pharmaceuticals (SVNT) to Underperform

Back to SVNT Stock Lookup